Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cipla's Advair generic hits Europe; eyes Breo version?

This article was originally published in Scrip

Executive Summary

Cipla has launched a "cost-efficient" generic version of GlaxoSmithKline's blockbuster asthma/COPD product, Advair/Seretide (salmeterol/fluticasone), in Germany and Sweden.

You may also be interested in...



Christmas Cheer For Cipla’s Seretide Equivalent In The UK

Cipla's generic version of Seretide has finally received regulatory approval in the UK, bringing much needed relief to investors and opening up more competition for GlaxoSmithKline on its home turf.

Christmas Cheer For Cipla’s Seretide Equivalent In The UK

Cipla's generic version of Seretide has finally received regulatory approval in the UK, bringing much needed relief to investors and opening up more competition for GlaxoSmithKline on its home turf.

India Regulatory Diary: Marketers Co-Accountable For Lapses In Manufacturing Quality

New rules in India specify that a marketer of a drug will share the onus for quality and compliance along with the manufacturer. Enhanced punishment for misleading advertisements for a range of illnesses is also proposed, while calls for a statute to regulate pharma's marketing practices grow louder.

Topics

Related Companies

UsernamePublicRestriction

Register

SC026224

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel